Merck Animal Health Accepts Top Honors
from Animal Pharm

Merck Animal Health received two prestigious awards from Animal Pharm, the most widely read publication reporting on the animal health industry. Richard DeLuca, president of Merck Animal Health, was recognized with the 2020 Visionary/CEO award and NOBILISĀ® SALENVACĀ® ETC was awarded with the 2020 Best New Food Animal Product award.

Rick received the 2020 Visionary/CEO award, for his vision and leadership of the companyā€™s animal health business over the past seven years, creating a company that continues to have robust growth with a strong and growing global presence.

ā€œWhat makes the animal health industry unique is the ability to offer customers — veterinarians, farmers, producers and pet owners — with the products, services and solutions to help, improve or enhance health outcomes and the well-being of animals,ā€ said Rick in receiving the honor.  ā€œWhile I am humbled by this recognition, I truly appreciate that we would not be where we are today without the great people of Merck Animal Health.ā€

NOBILIS SALENVAC ETC for poultry received the 2020 Best New Food Animal Product award. It is an inactivated, intramuscular, two-dose trivalent Salmonella vaccine, which offers the broadest protection for layers and breeders against three different Salmonella serogroups (B-C-D). This vaccine, the first registered and launched in the European Union in 2020, was developed based on the need for broad Salmonella food safety control in poultry farms. 

ā€œOur poultry portfolio of vaccines, health management solutions and value-added services continues to be strengthened with many notable scientific and commercial breakthroughs,ā€ said KJ Varma, BVSc, PhD, senior vice president, Research and Development, Merck Animal Health. ā€œSalmonellosis is one of the most frequently reported zoonotic diseases in humans with poultry meat and eggs often identified as a potential source of infection. Extensive efforts from our research and development team went into this technology, as it is the third-generation vaccine within the companyā€™s SALENVAC range, built upon a proven scientific platform.ā€

ā€œWe expect this newly launched product will become a mainstay in the fight against Salmonella food safety infections in the poultry industry and will positively impact an environment where food safety, animal welfare and well-being, as well as responsible use of antibiotics is of increasing importance,ā€ said Taylor Barbosa, executive director, Global Marketing, Poultry, Merck Animal Health. ā€œAddressing this significant OneHealth issue is critically important to both poultry and human health. It helps protect poultry health and advances a safe food supply.ā€ 

The Best New Food Animal Product award is also the third year in a row that technology from Merck Animal Healthā€™s vaccine portfolio has won this award. ā€œIt is a true testament to our R&D organization,ā€ said Dr. Varma. Last year, the company accepted this honor for PORCILISĀ® Lawsonia vaccine for piglets, the first, inactivated, one-dose, lyophilized (freeze-dried) intramuscular bacterial vaccine for piglets from three weeks of age against Lawsonia intracellularis. The year before, the company won the award for the IDALĀ® family of devices as the ideal solution for implementing needle-free vaccination on the farm.

To read more about the award, click here for the Merck Animal Health news release which also contains a link to the Animal Pharm article.